Abstract:The clinical use of cis-diamminedichloridoplatinum(II) (cisplatin, CDDP) is restricted by severe side effects, including nephrotoxicity, peripheral neuropathy, and ototoxicity. Although the nanoparticles has been used for CDDP delivery in animal models and demonstrated to reduce the side effects and increase the antitumor effects of CDDP, most of studies used none-targeted nanoparticles for CDDP delivery via enhanced permeability and retention (EPR) effect. However, utilizing EPR effect for delivery of CDDP achieves only passive tumor targeting. We have developed novel nanoparticles by conjugating single-chain antibodies to epidermal growth factor receptor (ScFvEGFR) to modified heparin, and loaded CDDP into the targeted nanoparticles (EHDDP). Our results showed that the intracellular Pt was significantly higher in EHDDP treated cells (27.91± 2.45 ng Pt/105 cells) than that of free DDP (2.49± 0.39 ng Pt/105 cells) (P=0.004) and non-targeted nanopartcles HDDP(2.14± 0.20 ng Pt/105 cells) (P=0.003) at 4 hrs, while the internalization of Pt in free CDDP treated cells didn9t show any significant difference as compared with that in HDDP (P=0.25). The Pt (166.05±21.17pg Pt/ug DNA) which was intercalated into DNA in EHDDP treated cells increased significantly as compared with that in CDDP(42.34±10.57pg Pt/ug DNA) (P=0.015) and HDDP(20.27±2.88 pg Pt/ug DNA) (P=0.008) treated cells. We found that the CDDP-loaded nanoparticles could significantly change the biodistribution of Pt in mice comparing with the free CDDP. Accumulation of Pt in subcutaneous tumor lesions in EHDDP group (13.45±2.15ng/mg dry tissue) was significant higher than that in HDDP (4.87±0.67ng/mg dry tissue) (P=0.026) and CDDP groups (1.48±0.52ng/mg dry tissue) (P=0.02) 24 hours after the intravenously injection (Pt, 2.5mg/kg) into nude mice bearing H292 tumors. The systemic delivery of EHDDP (2.5 mg/kg; 5 times treatment at 3 days intervals) to mice showed significant enhanced antitumor activity with no body weight loss or damages to kidney, liver, and spleen, while the mice that received free CDDP had significant weight loss and massive organ damages. Our results suggest that EHDDP nanoparticles have the potential to be used for targeted therapy of cancer which expresses EGFR with reduced side effects. (Supported by P50CA128613). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4451. doi:10.1158/1538-7445.AM2011-4451

Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles.

Abstract 4451: Targeted therapy of lung cancer using ScFvEGFR-Heparin-Cisplatin nanoparticles

Nanoparticle Delivery of a Triple-Action Pt(iv) Prodrug to Overcome Cisplatin Resistance Via Synergistic Effect

Delivery of Platinum (II) Drugs with Bulky Ligands in Trans-Geometry for Overcoming Cisplatin Drug Resistance.

LHRH-peptide Conjugated Dextran Nanoparticles for Targeted Delivery of Cisplatin to Breast Cancer.

Estrone-targeted PEGylated Liposomal Nanoparticles for Cisplatin (DDP) Delivery in Cervical Cancer

Abstract 4750: Overcoming DDP Resistance Using Folic Acid-Heparin-ddp Nanoparticles

Self-assembled Metal-Phenolic Network Nanoparticles for Delivery of a Cisplatin Prodrug for Synergistic Chemo-Immunotherapy

Aptamer Functionalized Cisplatin-Albumin Nanoparticles for Targeted Delivery to Epidermal Growth Factor Receptor Positive Cervical Cancer

Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients

Self-Assembled Metal-Phenolic Network Nanoparticles Delivery of Cisplatin Prodrug for Synergistic Chemo-Immunotherapy

Cisplatin-loaded polymeric nanoparticles: characterization and potential exploitation for the treatment of non-small cell lung carcinoma.

Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer

Application of nanogold-cisplatin drug delivery system in laryngeal cancer chemoradiotherapy

Targeted Delivery of Cisplatin by LHRH-peptide Conjugated Dextran Nanoparticles Suppresses Breast Cancer Growth and Metastasis.

cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer

Prominent Enhancement of Cisplatin Efficacy with Optimized Methoxy Poly(ethylene Glycol)-Polycaprolactone Block Copolymeric Nanoparticles.

Delivery of Platinum(iv) Drug to Subcutaneous Tumor and Lung Metastasis Using Bradykinin-Potentiating Peptide-Decorated Chitosan Nanoparticles

Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles

Microneedle-Mediated Delivery of Lipid-Coated Cisplatin Nanoparticles for Efficient and Safe Cancer Therapy.

Lipid-Coated Cisplatin Nanoparticles Induce Neighboring Effect and Exhibit Enhanced Anticancer Efficacy